Cardiome Pharma brings Aggrastat to Russian market

| By | Ministry of Health Care, Pharmaceutical Distribution

Cardiome Pharma, a specialty pharmaceutical company, headquartered in Canada and focused on commercializing patent-protected hospital drugs, today announced that its affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice that will advance Aggrastat® (tirofiban hydrochloride) toward commercialization in Russia.

Aggrastat is indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) and is currently marketed in over 60 countries worldwide.

Under the terms of the license agreement, ZAO will be responsible for obtaining regulatory approvals for Aggrastat from Russia’s Ministry of Health, then executing the commercial launch and subsequent sale and marketing of Aggrastat in the territory.

“ZAO Firma Euroservice has a solid track record of regulatory and commercial expertise, obtaining necessary drug distribution approvals and the subsequent delivering of high-quality medications to hospitals and customers throughout Russia,” said Hugues Sachot, Cardiome’s Chief Commercial Officer. “Aggrastat is currently marketed in over 60 countries worldwide, and we’re pleased to be adding Russia as a new territory for distribution of this important medication.”

With a commercial presence and distribution network covering over 60 countries worldwide, Cardiome develops, acquires and commercializes brands for the in-hospital, acute care market segment.

Mikhail Lazarev, Director, Regulatory Affairs at ZAO Firma Euroservice commented, “The addition of Aggrastat to our hospital products line underscores our commitment to bringing high-quality products into the hands of the physicians and patients who need them. We look forward to filing a timely registration package for Aggrastat in one year time, and obtaining the required authorizations to advance this high-value product toward the market.”

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.